Newsletter

3 03, 2022

NSCLC: tepotinib, first therapy approved against the METex14 skipping alterations

Diatech Pharmacogenetics2022-03-03T11:12:44+01:00

Mehr erfahren

18 01, 2022

• 

  NSCLC: sotorasib first therapy approved against the KRAS G12C mutation

  NSCLC: sotorasib first therapy approved against the KRAS G12C mutation

  Newsletter

NSCLC: sotorasib first therapy approved against the KRAS G12C mutation

Diatech Pharmacogenetics2022-01-18T16:23:33+01:00

Mehr erfahren

4 11, 2020

NGS: made it Easy with Myriapod Dry!

Diatech Pharmacogenetics2020-11-04T16:29:45+01:00

Mehr erfahren

4 11, 2020

EasyPGX ready KRAS together with KRAS G12C inhibitors: one more weapon in the fight against cancer!

Diatech Pharmacogenetics2020-11-05T11:15:24+01:00

Mehr erfahren

1 10, 2020

Test auf DPD-Mangel – neue Leistung im EBM

Diatech Pharmacogenetics2020-11-04T10:17:43+01:00

Mehr erfahren

9 04, 2019

EasyPGX EGFR plus: The state of the art of therapy customization

Diatech Pharmacogenetics2019-04-09T16:32:49+02:00

Mehr erfahren

26 02, 2019

EASY PGX ready FL-DNA: the first and only kit that supports the early diagnosis of CRC

Diatech Pharmacogenetics2019-02-26T17:28:38+01:00

Mehr erfahren

3 08, 2018

The first and only kit that supports the diagnosis of colorectal cancer by avoiding unnecessary coloscopy

Diatech Pharmacogenetics2018-08-03T14:39:04+02:00

Mehr erfahren

15 07, 2018

EasyPGX ready to yoUSE: dedicated kits for thyroid tumors enhance the current catalogue

Diatech Pharmacogenetics2018-07-15T12:41:12+02:00

Mehr erfahren

10 07, 2018

EasyPGX EGFR plus: the state of the art of therapy customization

Diatech Pharmacogenetics2018-07-10T13:20:33+02:00

Mehr erfahren